MET and non-small cell lung carcinoma: Many of these molecularly defined subsets of lung malignancies, such as those with mutations in HER2, MET, and BRAF genes, or fusions in genes such as ROS1, RET, and NTRK, occur in one or two percent of patients with non-squamous NSCLC.